ZIOPHARM Oncology Inc (ZIOP)

6.18
0.11 1.75
NASDAQ : Health Care
Prev Close 6.29
Open 6.31
Day Low/High 6.16 / 6.34
52 Wk Low/High 4.46 / 14.93
Volume 581.79K
Avg Volume 1.05M
Exchange NASDAQ
Shares Outstanding 141.96M
Market Cap 881.59M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

More Immunotherapy Buyouts Likely After Kite Sale

ZIOPHARM Oncology To Participate At Upcoming CAR-TCR Summit

ZIOPHARM Oncology To Participate At Upcoming CAR-TCR Summit

Data Highlighting the Non-viral Sleeping Beauty Gene Delivery System to Be Presented during Oral Session

First Week of April 2018 Options Trading For ZIOPHARM Oncology (ZIOP)

Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the April 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results And Provides Update On Recent Activities

ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results And Provides Update On Recent Activities

Company to Host Conference Call Today at 4:30 p.m. ET

ZIOPHARM Oncology Announces Initiation Of Stereotactic Treatment Cohort In Phase 1 Study Of Ad-RTS-hIL-12 + Veledimex In Recurrent Glioblastoma

Stereotactic Study Arm Serves as Runway to Clinical Studies of Controlled IL-12 Gene Therapy in Pediatric Patients and in Combination with Checkpoint Inhibitors

ZIOPHARM Oncology Enters Oversold Territory (ZIOP)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ZIOPHARM Oncology Announces Results Of Ad-RTS-hIL-12 + Veledimex In Recurrent Glioblastoma To Be Presented At The 2017 ASCO Annual Meeting

- Updated Survival Through Late May to be Presented on June 5, 2017 -

Notable Tuesday Option Activity: ZIOP, FEYE, CHGG

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ZIOPHARM Oncology Inc , where a total of 8,160 contracts have traded so far, representing approximately 816,000 underlying shares. That amounts to about 62.6% of ZIOP's average daily trading volume over the past month of 1.3 million shares.

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

First Week of June 16th Options Trading For ZIOPHARM Oncology (ZIOP)

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new June 16th contracts and identified one put and one call contract of particular interest.

Judgment Day; The Good, the Bad and the Ugly: Doug Kass' Views

Judgment Day; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on whether Judgment Day is here for the financials and discusses General Electric, Apple and Caterpillar.

Intrexon, ZIOPHARM And Merck KGaA, Darmstadt, Germany Advancing Next-Generation Non-Viral CAR-T Platform Empowered By Membrane-Bound IL-15 Under RheoSwitch Therapeutic System® Control

Two CAR Targets Selected Enable Range of Potential Therapeutic Candidates for Both Solid and Liquid Tumors

ZIOPHARM Appoints Amy Trevvett Vice President Of Investor Relations And Corporate Communications

Company to Host Quarterly Conference Calls

Twitter, Netflix, MetLife: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Doug Kass shares his thoughts on Twitter and talks about Sears.

First Week of ZIOP May 19th Options Trading

Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

ZIOPHARM Oncology Breaks Below 200-Day Moving Average - Notable for ZIOP

In trading on Tuesday, shares of ZIOPHARM Oncology Inc crossed below their 200 day moving average of $5.89, changing hands as low as $5.85 per share. ZIOPHARM Oncology Inc shares are currently trading off about 6.2% on the day.

Don't Overlook Ziopharm Oncology

Don't Overlook Ziopharm Oncology

The stock is poised for an upside breakout.

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Here's how to rake in the profits off some potential big breakouts.

TheStreet Quant Rating: D (Sell)